AstraZeneca Balance Sheet Health
Financial Health criteria checks 3/6
AstraZeneca has a total shareholder equity of $39.6B and total debt of $32.4B, which brings its debt-to-equity ratio to 81.8%. Its total assets and total liabilities are $104.3B and $64.7B respectively. AstraZeneca's EBIT is $12.3B making its interest coverage ratio 13.6. It has cash and short-term investments of $7.1B.
Key information
81.8%
Debt to equity ratio
US$32.40b
Debt
| Interest coverage ratio | 13.6x |
| Cash | US$7.08b |
| Equity | US$39.60b |
| Total liabilities | US$64.74b |
| Total assets | US$104.34b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ZEG's short term assets ($25.4B) do not cover its short term liabilities ($28.6B).
Long Term Liabilities: ZEG's short term assets ($25.4B) do not cover its long term liabilities ($36.2B).
Debt to Equity History and Analysis
Debt Level: ZEG's net debt to equity ratio (64%) is considered high.
Reducing Debt: ZEG's debt to equity ratio has reduced from 139.7% to 81.8% over the past 5 years.
Debt Coverage: ZEG's debt is well covered by operating cash flow (34.1%).
Interest Coverage: ZEG's interest payments on its debt are well covered by EBIT (13.6x coverage).